What happened with STRO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Sutro Biopharma is a clinical-stage cancer drug developer focused on linking drug payloads to antibodies, creating antibody-drug conjugates, or ADCs. Its XpressCF and XpressCF+ platforms make proteins without growing additional cell lines and provide defined attachment sites for payloads. It develops its own candidates, including clinical-stage STRO-004, and works on partners’ programs. It has no approved products or commercial product sales; collaboration and license agreements provide most of its revenue, with supplies and services contributing less.
Astellas is an important ongoing partner. Sutro performs research and preclinical development, while Astellas holds exclusive worldwide rights to develop and commercialize designated compounds. Sutro can earn milestone payments as programs advance and royalties if products reach the market, with an option to share U.S. costs and profits instead. These payments depend on Astellas continuing development and on programs reaching the required milestones and approvals. The former Ipsen license for STRO-003 ended in 2025.
Sutro also licenses its technology to Vaxcyte for infectious-disease vaccines and supplies XtractCF materials and technical support. Vaxcyte pays for supplies on a cost-plus basis and has obtained rights to make and source the extract itself. Sutro retains potential royalties on Vaxcyte’s non-pneumococcal vaccines, but Blackstone holds the royalty interest in pneumococcal candidates such as VAX-24 and VAX-31. Sutro now relies on contract manufacturers for its drug candidates and platform reagents.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Sutro’s prospects hinge on its own antibody-drug conjugate trials and Astellas’s partnered immune-stimulating ADC development, with Astellas supplying nearly all recurring collaboration revenue in 2025 after revenue recognition tied to Ipsen’s termination.
Vaxcyte pays Sutro to license its cell-free technology and buy extracts, reagents and technical support for vaccine development. Watch vaccine progress for potential regulatory milestone payments, but royalties from lead pneumococcal candidates VAX-24 and VAX-31 belong to Blackstone, not Sutro.
Pfizer competes directly with Sutro by selling TIVDAK, an approved cancer drug that uses an antibody to deliver a drug payload to tissue-factor targets, and developing ITGB6-targeting antibody-drug conjugates (ADCs). Its ITGB6 trial results are worth watching alongside Sutro’s preclinical STRO-006, while TIVDAK already competes in STRO-004’s target area.
Immunome and Sutro face the same test: whether their proprietary solid-tumor drugs can use antibodies to deliver drug payloads effectively with tolerable side effects. Progress in Immunome’s preclinical IM-1617, IM-1340 and IM-1335 offers another read on this antibody-drug conjugate approach, though it does not establish how Sutro’s own candidates will perform.
Bristol Myers Squibb’s development decisions directly affect its partnered work with Sutro, using Sutro’s protein-engineering platforms to build antibodies that deliver drug payloads to BCMA targets. For Sutro holders, progress in this BCMA antibody-drug conjugate program matters more to the tie than Bristol Myers Squibb’s broader medicine sales.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s report will show whether it is advancing the partnered BCMA antibody-drug conjugate program, revealing whether Sutro’s platform collaboration is opening a path to further development.
Focus on Bristol Myers Squibb’s disclosed progress in the BCMA program, not its overall drug sales. Continued development would show the collaboration is active and leave Sutro a path to potential development milestone payments; a pause or end would weaken that potential revenue path, but would not reveal how Sutro’s other programs are doing.
Vaxcyte, Inc. earningsPCVX
Vaxcyte’s report will show whether vaccine development is moving toward regulatory milestones that could bring Sutro additional payments, while royalties on VAX-24 and VAX-31 belong to Blackstone.
Look for Vaxcyte’s disclosed development progress and whether a regulatory milestone that triggers payment is getting closer. Progress would improve the prospect of additional milestone cash for Sutro; delays would push that potential revenue further out. Do not count prospective VAX-24 or VAX-31 royalties as Sutro revenue: Blackstone holds that revenue interest.
Sutro Biopharma, Inc. earningsThis company
Sutro Biopharma has no products for sale and relies on collaboration revenue, so this report shows how partner work and research spending shape the resources it has to advance its antibody-drug conjugate programs.
Read collaboration revenue alongside research and development spending and cash used in operations, then check the disclosed program progress. Rising partner revenue, program advances and controlled cash use would show collaborations supporting development; weaker revenue, limited progress or faster cash use would mean Sutro needs more outside financing to keep developing its candidates.
